Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 1024Carboplatin 966Paclitaxel 933Gemcitabine 794Cisplatin 753Docetaxel 684Bevacizumab 609Pemetrexed 504Nivolumab 487Cyclophosphamide 474Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 373Oxaliplatin 348Injections 347atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 246Doxorubicin 241Ipilimumab 226fludarabine 220Lenalidomide 220Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × satralizumab × Clear all
NCT04963270 2025-02-28

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Hoffmann-La Roche

Phase 3 Terminated
188 enrolled 40 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡